Buradasınız

Anasayfa » Content

Omega-3 ve omega-6 yağ asitlerinin özellikleri, etkileri ve kardiyovasküler hastalıklar ile ilişkileri

Properties, functions of omega-3 and omega-6 fatty acids and relationship between essential fatty acids and cardiovasculer diseases

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2008
DOI: 
doi:10.2399/tahd.08.121

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Essential fatty acids (EFAs) are essential for survival of humans and other mammals, and they can not be synthesized in the body; hence, they have to be obtained by the diet. There are two types of naturally occurring EFAs in the body, the omega-6 (co-6) series derived from cis-linoleic acid and the omega-3 series (co-3) derived from a-linolenic acid (ALA, 18:3). co-3 and co-6 fatty acids display a variety of beneficial effects on various organ systems and diseases. The metab¬olism of EFAs is altered in several diseases such as obesity, hyperten¬sion, diabetes mellitus, coronary heart disease, schizophrenia, Alzheimer's disease, atherosclerosis, and cancer. In this paper, we review both the structure properties and metabolisms of fatty acids and the relationship between EFAs and cardiovascular diseases.
Bookmark/Search this post with
Abstract (Original Language): 
Esansiyel yağ asitleri (EYA) insan ve diğer memelilerde yaşam için mutlak gerekli olan ve vücutta sentezlenemediğinden diyetle alınması gereken yağ asitleridir. Vücutta doğal olarak iki tipi bulunur. Omega-6 (co-6) serisi cis-linoleik asitten, omega-3 (co-3) serisi a-li-nolenik asitten kaynaklanır. co-3 ve co-6 yağ asitlerinin çeşitli organ ve hastalıklarda yararlı etkileri bulunur. EYA metabolizması obezi-te, hipertansiyon, diyabetes mellitus, koroner kalp hastalıkları, şizofreni, Alzheimer hastalığı, ateroskleroz ve kanser oluşumunda değişir. Bu derlemede yağ asitlerinin yapısal özellikleri ve metabolizmaları ile kardiyovasküler hastalıklarla ilişkileri gözden geçirilmiştir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_12_pp_121-129.pdf
  • 3
121-129
  • Turkish

REFERENCES

References: 

1. Bang HO, Dyerberg J. Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand 1972; 192: 85-94.
2. Dyerberg J, Bang HO, Hjorne N. Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 1975; 28: 958-66.
3. Das UN. Essential fatty acids: biochemistry, physiology and pathology. Biotechnol J 2006; 1: 420-39.
4. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic pers¬pectives. Atherosclerosis 2007; 197: 12-24.
5. Das NU. Essential fatty acids- A review. Curr Pharm Biotechnol 2006; 7:
467-82.
6. Nakamura MT, Nara TY. Structure, function, and dietary regulation of A6, A5, and A9 desaturases. Annu Rev Nutr 2004; 24: 345-76.
7. Brenner RR. Nutritional and hormonal factors influencing desaturation of essential fatty acids. Prog Lipid Res 1982; 20: 41-8.
8. Tang C, Cho HP, Nakamura MT, Clarke SD. Regulation of human del-ta-6 desaturase gene transcription: identification of a functional direct re-
peat-1 element. J Lipid Res2003; 44: 686-95.
9. Das UN. A defect in the activity of A6 and A5 desaturases may be a factor predisposing to the development of insulin resistance syndrome. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 343-50.
10. Horrobin DF. The regulation of prostaglandin biosynthesis by the mani¬pulation of essential fatty acid metabolism. Rev Pure Appl Pharmacol Sci
1983; 4: 339-83.
11. Meyer BJ, Mann NJ, Lewis JL ve ark. Dietary intakes and food sources of omega-6 and omega-3 polyunsaturated fatty acids. Lipids2003; 38: 391-8.
12. Sanders TAB. Essential and trans-fatty acids in nutrition. Nutr Res Rev 1988; 1: 57-8.
13.
Taşa
n M. Dağlıoğlu O. Trans yağ asitlerinin yapısı, oluşumu ve gıdalarla alınması. Tekirdağ Ziraat Fakültesi Dergisi 2005; 2: 79-88.
14. Mensink RP, Katan MB. Effect of dietary trans fatty acids on high-den¬sity and low-density lipoprotein cholesterol levels in healthy subjects. N Eng J Med 1990; 323: 439-45.
15. Sackh FM, Stone PH, Gibson CM, Silverman DI, Rosner B, Pasternak RC. Controlled trial of fish oil regression of human coronary atheroscle¬rosis. HARP Research Group. J Am Cardiol1995; 25: 1492-8.
16. Yokoyama M, Origasa H, Matsuzaki M ve ark. On behalf of the Japan EPA Lipid Intervention Study (JELIS) Investigators. Effects of eicosa-pentaenoic acid on major coronary events in hypercholesterolaemic pati-
ents: a randomised open-label, blinded endpoint analysis. Lancet 2007;
369: 1090-8.
17. Richter WO, Jacob BG, Ritter MM, Schwandt P. Treatment of primary chylomicronemia due to familial hypertriglyceridemia by omega-3 fatty acids. Metabolism 1992; 41: 1100-5.
18. Dehmer GJ, Popma JJ, van den Berg EK ve ark. Reduction in the rate of early restenosis after coronary angioplasty by a diet supplemented with n-
3 fatty acids. N Engl J Med1988; 319: 733-40.
19. Leaf A. Dietary prevention of coronary heart disease: the Lyon Diet He¬art Study. Circulation 1999; 99: 733-5.
20. De Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet
Heart Study. Circulation 1999; 99: 779-85.
21. Marchioli R, Schweiger C, Tavazzi L, Valagussa F. Efficacy of n-3 pol-yunsaturated fatty acids after myocardial infarction: results of GISSI-Pre-venzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'In-farto Miocardico. Lipids2001; 36: 119-26.
22. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized con¬trolled trials. Am J Med2002; 112: 298-304.
23. Oomen CM, Ocke MC, Feskens EJ, Kok FJ, Kromhout D. Alpha-Lino-
lenic acid intake is not beneficially associated with 10-y risk of coronary artery disease incidence: the Zutphen Elderly Study. Am J Clin Nutr
2001; 74: 457-63.
24. Nilsen DW, Albreksten G, Landmark K, Moen S, Aarsland T, Woie L. Effects of a high-dose concentrate of n-3 fatty acids or corn oil introdu¬ced early after an acute myocardial infarction on serum triacylglycerol and HDL cholesterol. Am J Clin Nutr 2001; 74: 50-6.
25. Schacky C. Omega-3 fatty acids and cardiovascular disease. Curr Opin
Clin Nutr Metab Care 2007; 10: 129-35.
26. De Caterinaa R, Zampolli A. Omega-3 fatty acids, atherogenesis, and en-dothelial activation. Cardiovasc Med 2007; 8: 11-4.
27. Harris WS, von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 2004; 39: 212-20.
28. von Schackya C, Haris WS. Cardiovascular risk and the omega -3 index.
J Cardiovasc Med2007; 8: 46-9.
29. Nakamura N, Ohta M, Okuda K ve ark. Joint effects of HMG-CoA re-ductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia. Int J Clin Lab Res 1999; 29: 22-5.
30. Bezard J, Blond J, Bernard A, Clouet P. The metabolism and availability of essential fatty acids in animal and human tissues. Semin Nephrol 1994;
34: 539-68.
31. Collins T, Read MA, Neish AS, Whitley MZ, Thanos D, Maniatis T.
Transcriptional regulation of endothelial cell adhesion molecules: NF-
kappa B and cytokine-inducible enhancers. FASEB J1995; 9: 899-909.
32. Bonaa KH, Bjerve KS, Nordoy A. Docosahexaenoic and eicosapentaeno-ic acids in plasma phospholipids are divergently associated with high den¬sity lipoprotein in humans. Arterioscler Thromb 1992; 12: 675-81.
33. Riserus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab
Care 2008; 11: 100-5.
34. Nakamura N, Hamazaki T, Jokaji H, Minami S, Kobayashi M. Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid
>5
LU O H
128
Konukoğlu D | Omega-3 ve omega-6 yağ asitlerinin özellikleri, etkileri ve kardiyovasküler hastalıklar ile ilişkileri
concentration in patients with hyperlipidemia. Int J Clin Lab Res1998; 28:
192-5.
35. Narayanan BA, Narayanan K, Simi B, Reddy BS. Modulation of ınducib-le nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res
2003; 63: 972-9.
36. Kumar KV, Das UN. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proc Soc Exp Biol Med 1997; 214: 374-9.
37. Kaergel E, Muller DN, Honeck H, Theuer J ve ark. P450-dependent arachidonic acid metabolism and angiotensin-II-induced renal damage. Hypertension 2002; 40: 273-9.
38. Danao-Camara TC, Shintani TT. The dietary treatment of inflammatory arthritis: case reports and review of the literature. Hawaii Med J 1999; 58:
126-31.
39. Li H, Ruan XZ, Powis SH, Fernando R ve ark. EPA and DHA reduce LPS-induced inflammation responses in HK -2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int 2005; 67: 867-74.
40. Okuda Y, Kawashima K, Sawada T ve ark. Eicosapentaenoic acid enhan¬ces nitric oxide production by cultured human endothelial cells. Biochem BiophysRes Commun 1997; 232: 487-91.
41. Marcheselli VL, Hong S, Lukiw WJ ve ark. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyteinfiltration and pro-inf¬lammatory gene expression. J Biol Chem 2003; 278: 43807-17.
42. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammati¬on. J Biol Chem 2003; 278: 14677-87.
43. Simopoulos AP, Leaf A, Salem Jr N. Statement on the essentiality of and recommended dietary intakes for co-6 and co-3 fatty acids. Prostaglandins Leukot Essent Fatty Acids2000; 63: 119-21.
44.
45.
Din JN,Newby DE, Flapan AD. Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment. BMJ2004; 328; 30-5.
Goyens PL, Spilker ME, Zock PL, Katan MB, Mensink RP. Conversion of alpha-linolenic acid in humans is influenced by the absolute amounts of alpha-linolenic acid and linoleic acid in the diet and not by their ratio. Am J Clin Nutr 2006; 84: 44-53.
46. Willett WC. The role of dietary n-6 fatty acids in the prevention of car¬diovascular disease. J Cardiovasc Med 2007; 8: 42-5.
Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. Am J Clin Nutr 2003; 77: 1146-55.
Sacks FM, Campos H. Polyunsaturated fatty acids, inflammation, and cardiovascular disease: time to widen our view of the mechanisms. J Clin
Endocrinol Metab 2006; 91: 398-400.
Mozaffarian D, Ascherio A, Hu FB ve ark. Interplay between different polyunsaturated fatty acids and risk of coronary heart disease in men. Cir¬culation 2005; 111: 157-64.
Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm
EB. Habitual dietary intake of n- 3 and n-6 fatty acids in relation to inf-lammatorymarkers among US men and women. Circulation2003; 108: 55¬160.
Hu FB, Manson JE, Stampfer MJ ve ark. Diet, lifestyle, and the risk of
type 2 diabetes mellitus in women. N Engl J Med2001; 345: 790-7.
Kris-Etherton PM, Harris WS, Appel LJ. Omega-3 fatty acids and cardi¬ovascular disease: new recommendations from the American Heart Asso¬ciation. Arterioscler Thromb Vasc Biol 2003; 23: 151-2.
Schwalfenberg G. Omega-3 fatty acids, their beneficial role in cardiovas¬cular health. Can Fam Physician 2006; 52: 734-40.
Nordoy A, Marchioli R, Arnesen H, Videbaek J. n-3 polyunsaturated fatty acids and cardiovascular diseases. Lipids2001; 36: 127-9.

Thank you for copying data from http://www.arastirmax.com